Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP)
Phase 1
- Conditions
- fibrodysplasia ossificans progressiva
- Registration Number
- JPRN-UMIN000019348
- Lead Sponsor
- agoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
Skeletally immature patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total bone volume before the intervention, at the end of medication, and at the end of the study
- Secondary Outcome Measures
Name Time Method serum alkaline phosphatase and osteocalsin concentration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does perhexiline maleate modulate ACVR1 signaling in FOP patients with heterotopic ossification?
What are the comparative efficacy and safety profiles of perhexiline versus standard-of-care treatments for FOP?
Which biomarkers predict response to perhexiline in JPRN-UMIN000019348 FOP trial sponsored by Aoyama Gakuin University?
What adverse events are associated with perhexiline use in FOP and how are they managed?
How do calcium channel blockers like perhexiline compare to other phosphodiesterase inhibitors in targeting FOP pathogenesis?